Rosuvastatin
- PDF / 205,271 Bytes
- 20 Pages / 592.44 x 751.18 pts Page_size
- 83 Downloads / 150 Views
Am J Cardiovasc Drugs 2008; 8 (2): 127-146 1175-3277/08/0002-0127/$48.00/0 © 2008 Adis Data Information BV. All rights reserved.
Rosuvastatin A Review of its Effect on Atherosclerosis Gillian M. Keating and Dean M. Robinson Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA Various sections of the manuscript reviewed by: A.S. Binbrek, Department of Cardiology, Rashid Hospital, Dubai, United Arab Emirates; J.K. Ghali, Wayne State University, Detroit, Michigan, USA; A. Vogt, Lipidambulanz, Lipidapherese und Ern¨ahrungsmedizin, Interdisziplin¨ares Stoffwechsel-Centrum, Charit´e, Virchow-Klinikum, Humboldt-Universit¨at zu Berlin, Berlin, Germany; K.E. Watson, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; G.F. Watts, School of Medicine and Pharmacology, Royal Perth Hospital, Perth, Western Australia, Australia; R.J. Weiss, Androscoggin Cardiology Research, Auburn University, Auburn, Maine, USA.
Data Selection Sources: Medical literature published in any language since 1980 on ‘rosuvastatin’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health | Adis). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘rosuvastatin’ and ‘atherosclerosis’. Searches were last updated 3 March 2008. Selection: Studies in patients with atherosclerosis who received rosuvastatin. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Rosuvastatin, atherosclerosis, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.
Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 2. Pharmacodynamic Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130 2.1 Mechanism of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130 2.2 Lipid-Lowering Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
